Accession Number:
AD1120858
Title:
Phase I Trial of Intratumoral Administration of NIS-Expressing Strain of Measles Virus in Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor
Descriptive Note:
[Technical Report, Annual Report]
Corporate Author:
Mayo Clinic
Personal Author(s):
Report Date:
2020-10-01
Pagination or Media Count:
10
Abstract:
Study approved by Mayo IRB on April 18, 2016, and by USAMRMCORPHRPO on May 6, 2016. All study staff completed IRB training. Dose volume charts have been developed to facilitate pharmacy orders. Study opened for enrollment on May 17, 2016. Study coordinators identified and assigned to the study by Mayo Clinic Cancer Center. Five patients have been enrolled in the study. They completed treatment per protocol and continue the follow up. None of the treated patients experienced side effects. With the first 3 patients we have completed the first dose level, and two patients have been treated by dose 2 level. Accrual of the third patient into dose 2 is ongoing. So far out of 5 treated patients two died to cancer progression. Others are undergoing follow up. A few additional patients are under evaluation for eligibility at this time.
Descriptors:
- peripheral nervous system
- neoplasms
- oncolytic viruses
- viruses
- biomedical research
- clinical trials
- department of defense
- therapy
- abstracts
- neurofibromatosis
- training
- electronic mail
- pharmacies
- technology transfer
- diseases and disorders
- gene expression
- health services
- information operations
- patent applications
- standards
Subject Categories:
- Medicine and Medical Research